Therapeutic Solutions International Inc (OTCMKTS:TSOI) has announced the successful treatment of a U.S Navy Seal veteran with Chronic Traumatic Encephalopathy (CTE). The patient was treated with two injections of the JadiCell adult stem cells. Doctors did not observe any adverse effects.
Therapeutic Solutions International have a new program that gives access to its technologies to members of the Armed Forces who have defended the U.S Pro Bono. As such, they provided the JadiCells adult stem cells to the U.S veteran. Therapeutic Solutions International is a company that focuses on immune modulation to treat various diseases.
CTE is a disease caused by repeated injury to the brain. It leads to chronic brain injury, deterioration in neuronal communication, and the death of brain cells. Symptoms associated with the disease include violence, depression, and suicidal tendencies.
Therapeutic Solutions is intent on conducting clinical trials to use these cells in patients with COVID-19 ARS. It is also working with the FDA to launch phase I and phase Ii clinical trials in CTE. The suicide rate among veterans is 20 per day, making treatment of CTE crucial.
Market Reaction:
On Monday, TSOI stock fell 3.61% at $0.0800 with more than 8.55 million shares, compared to its average volume of 14.49 million shares. The stock has moved within a range of $0.0780 – 0.0930 after opening the trade at $0.0900.
